Antibody details can be found in the Supplementary Table 1
E., Rasmussen, S., Vilsbll, T., Wolthers, B., & Perkovic, V
For Healthcare Providers: Doctors and weight management specialists should: Inform patients about FDA-approved alternatives to compounded GLP-1 medications
Research on GLP-1 maintenance suggests this may preserve 75%+ of weight loss efficacy while reducing cost and side effect burden
Additionally, the anti-inflammatory effects of semaglutide could play a role in reducing chronic pain associated with conditions like arthritis or other inflammatory disorders
For example, if the group exposed to GLP-1 RAs included more women with obesity or diabetes, and both of those conditions are independently linked to kidney malformations, that could help explain the observed association